Get the free digest
Health

FDA warns GLP-1 drugs may pose risk of rare condition that causes vision loss

The Food and Drug Administration is warning that popular obesity drugs—including Ozempic, Wegovy, Zepbound, and Mounjaro—may carry a "potential increased risk" of a rare eye condition that can lead to permanent vision loss.

✦ Extractive summary — built from the sources' own reporting•From 3 sources•1 min read•Updated November 10, 2026, 2:43 PM UTC
Key points
  • In a drug safety communication Monday, the FDA said it will now require makers of GLP-1 receptor agonist drugs to add a warning about that risk on their drug labels.
  • The condition is caused by restricted blood flow to the optic nerve, which leads to swelling and cell death and ultimately damages the nerve, causing abrupt vision loss that can often be permanent.
  • GLP-1 drugs such as Novo Nordisk’s Ozempic and Wegovy and Eli Lilly’s Mounjaro and Zepbound have exploded in popularity for their potent weight loss effects, but as with any drugs that are given to large populations, side effects can show up in real-world use that weren’t observed in clinical trials.

The agency has found evidence of a potential increased risk of a rare eye condition linked to the use of GLP-1 drugs used for weight management and diabetes.

Additional details
  • Further complicating the potential link is the fact that the risk factors for developing NAION are common among patients taking GLP-1 drugs.
  • The condition is rare overall, occurring in somewhere between two and 10 people in 100,000 in the general population, according to the American Academy of Ophthalmologists.
  • It's unknown how GLP-1 drugs may cause NAION.
  • The specific eye condition it warns of is called non-arteritic anterior ischemic optic neuropathy or NAION.
  • It typically causes sudden vision loss and, in severe cases, can lead to blindness.

How this summary was made: extractive summary — built from the sources' own reporting. It is drawn only from the reporting of the sources listed below — read the originals for full detail. How we summarize →

Advertisement

Every article behind this summary — 4 articles from 3 outlets

Ars TechnicaNovember 10, 2026, 2:43 PM UTC → CNBCNovember 10, 2026, 2:43 PM UTC → STAT NewsNovember 10, 2026, 2:38 PM UTC → STAT NewsNovember 9, 2026, 3:56 PM UTC →

Related stories